Medical Condition News

RSS

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.

29 Apr 2013

Veloxis seeks EMA approval to market LCP-Tacro for kidney transplant patients

Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.

29 Apr 2013

Oxford BioTherapeutics, Boehringer Ingelheim team up to discover novel cancer antibody targets

Oxford BioTherapeutics and Boehringer Ingelheim today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.

29 Apr 2013

Heart Failure Congress 2013 to feature more than 100 scientific sessions on heart failure

The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. The congress takes place 25-28 May at the Centro de Congressos de Lisboa in Lisbon, Portugal.

29 Apr 2013

Study may pave way for new strategies to fight cancer cells

For the first time, researchers at Karolinska Institutet in Sweden have managed to obtain detailed images of the way in which the transport protein GLUT transports sugars into cells.

29 Apr 2013

Research provides new insights into the origin of brown fat cells

Scientists from ETH Zurich have shown for the first time that brown and white fat cells in a living organism can be converted from one cell type to the other.

29 Apr 2013

GWCI research focuses on real needs of adolescent, young adult cancer survivors

New research out of the George Washington University Cancer Institute focuses on the difficulties of transitioning to adulthood while dealing with the long-term and late effects of cancer and its treatment.

29 Apr 2013

UAB expert offers simple strategies to tackle summer allergy season

Sneezing, wheezing and coughing are just some of the symptoms that seasonal allergies can stir up. One sinus expert at the University of Alabama at Birmingham said despite a late spring, the summer allergy season will be strong.

29 Apr 2013

Intermittent fasting: A path to weight loss and improved cardiovascular risk

Intermittent fasting is all the rage, but scientific evidence showing how such regimes affect human health is not always clear cut. Now a scientific review in the British Journal of Diabetes and Vascular Disease published by SAGE, suggests that fasting diets may help those with diabetes and cardiovascular disease, alongside established weight loss claims.

29 Apr 2013

New treatment strategy for patients with CMT disease on the horizon

A potential new treatment strategy for patients with Charcot-Marie-Tooth disease is on the horizon, thanks to research by neuroscientists now at the University at Buffalo's Hunter James Kelly Research Institute and their colleagues in Italy and England.

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia.

29 Apr 2013

Doctors assail drugmakers for $100K cancer medicines

More than 100 cancer specialists call for pharmaceutical companies to lower the prices of these drugs that patients need to live.

29 Apr 2013

UH professor wins grant to develop promising therapies for melanoma

A University of Houston engineering professor has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease.

29 Apr 2013

Researchers develop mobile phone app to support individuals embarking on partial MRP

Mobile phones using text messaging and monitoring have been shown to be useful additions to health programs. The objective of this study was to develop and evaluate a weight-loss intervention delivered by a smartphone app that supported individuals embarking on a diet and that was evidenced-based.

29 Apr 2013

Practical guidelines on the use of new oral anticoagulants

A practical guide on the use of the new oral anticoagulants has been produced by the European Heart Rhythm Association of the European Society of Cardiology.

29 Apr 2013

Study confirms that mesenchymal stem cells may help treat cancer

Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy.

29 Apr 2013

BIOMARGIN research project aims to prevent, diagnose lesions in transplanted kidneys

The BIOMARGIN (BIOMArkers of Renal Graft INjuries in kidney allograft recipients) research project, coordinated by INSERM, has just received financing from the "health" seventh framework programme of the European Commission to the tune of 6 million euros for a four-year period.

29 Apr 2013

Testosterone’s role in schizophrenia

Researchers from Neuroscience Research Australia (NeuRA) have presented new results about the role of testosterone in schizophrenia at the International Congress on Schizophrenia Research being held in Orlando, Florida.

26 Apr 2013

ACT announces European phase I clinical trial for Stargardt's disease using retinal pigment epithelial cells

Advanced Cell Technology, Inc. a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

26 Apr 2013